Technology
Health
Biotechnology

Kodiak Sciences

$14.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (0.76%) As of 11:38 AM EDT today
+$0.11 (0.76%) Today

Why Robinhood?

You can buy or sell KOD and other stocks, options, ETFs, and crypto commission-free!

About KOD

Kodiak Sciences Inc Common Stock, also called Kodiak Sciences, is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. Read More The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Employees
28
Headquarters
Palo Alto, California
Founded
2009
Market Cap
537.04M
Price-Earnings Ratio
Dividend Yield
Average Volume
196.51K
High Today
$14.87
Low Today
$14.44
Open Price
$14.64
Volume
42.51K
52 Week High
$14.88
52 Week Low
$5.65

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2018 IPO
US

KOD Earnings

-$1.33
-$0.96
-$0.58
-$0.21
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 13, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.